设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2020 年第 11 期 第 15 卷

帕金森病患者康复治疗药物利用研究

Study on rehabilitation drug utilization in patients with Parkinson′s disease

作者:杜广清1方伯言1刘爱贤1席家宁1李大魁2公维军1李文悦1杨阔1田红娇1

英文作者:Du Guangqing1 Fang Boyan1 Liu Aixian1 Xi Jianing1 Li Dakui2 Gong Weijun1 Li Wenyue1 Yang Kuo1 Tian Hongjiao1

单位:1首都医科大学附属北京康复医院康复药学中心100144;2北京协和医院药剂科100730

英文单位:1Rehabilitation Pharmacy Center Beijing Rehabilitation Hospital Capital Medical University Beijing 100144 China; 2Department of Pharmacy Peking Union Medical College Hospital Beijing 100730 China

关键词:帕金森病;康复药学;药物康复;药物利用

英文关键词:Parkinson′sdisease;Rehabilitationpharmacy;Drugrehabilitation;Drugutilization

  • 摘要:
  • 目的 对帕金森病患者康复治疗药物的临床使用及利用分析进行评价,为药师开展康复药学监护服务提供参考。方法 选择20181月至201912月在首都医科大学附属北京康复医院接受药物康复及康复技术治疗的帕金森病患者2 860 例,调取医院系统中抗帕金森病药物处方,对用药品种、用药频度、用药金额、限定日费用等药物利用指标进行评价,对联合用药情况进行分析。结果 抗帕金森病药物用药频度排序前5位的依次是多巴丝肼片、盐酸司来吉兰片、盐酸金刚烷胺片、卡左双多巴缓释片、盐酸普拉克索片。治疗药物总金额占比在5%以上的药品为盐酸普拉克索(包括普片和缓释片)、多巴丝肼片、恩他卡朋片、甲磺酸雷沙吉兰片以及盐酸司来吉兰片。限定日费用排序前5位依次是盐酸普拉克索缓释片、盐酸普拉克索片、甲磺酸雷沙吉兰片、恩他卡朋片和吡贝地尔缓释片。2 860例患者药物治疗方案为单一用药499例(17.45%)、二联用药831例(29.06%)、三联用药599例(20.94%)、四联及以上用药931例(32.55%)。结论 首都医科大学附属北京康复医院帕金森病患者康复治疗药物利用指标科学,联合治疗用药方案基本合理。建议药师根据实际情况为帕金森病患者提供康复药学监护服务。

  • Objective To analyze the use and rationality of drugs in the rehabilitation patients with Parkinsons disease; to provide a reference for rehabilitation pharmacy medicine services. Methods From January 2018 to December 2019, 2 860 patients with Parkinsons disease admitted to Beijing Rehabilitation Hospital, Capital Medical University were selected to receive drug rehabilitation and rehabilitation technology. The prescriptions of anti Parkinsons disease drugs in the hospital system were obtained. The drug types, defined daily dose system (DDDs), drug sales amount, defined daily cost (DDC) and combination medication were analyzed statistically. Results The top five DDDs of anti-Parkinsons disease drugs were levodopa and benserazide hydrochloride tablets, selegiline hydrochloride tablets, amantadine hydrochloride tablets, carbidopa and levodopa sustained-release tablets, pramipexole dihydrochloride tablets. The drug sale of more than 5% were pramipexole dihydrochloride tablets(included sustained-release tablets and controlled released tablets), levodopa and benserazide hydrochloride tablets, entacapone tablets, rasagiline mesylate tablets and selegiline hydrochloride tablets. The top five DDC of anti-Parkinsons disease drugs were pramipexole dihydrochloride sustained-release tablets, pramipexole dihydrochloride tablets, rasagiline mesylate tablets, entacapone tablets, piribedil sustained-release tablets. Totally 2 860 cases included 499 cases of single drug (17.45%), 831 cases of double drugs (29.06%), 599 cases of triple drugs (20.94%), 931 cases of quadruple drugs (32.55%). Conclusions The Parkinsons disease drugs treatement is basically reasonable in the rehabilitation patients in Beijing Rehabilitation Hospital, Capital Medical University. It is recommended that pharmacists provide pharmacy services for dysfunction patients with Parkinsons disease based on clinical conditions.

copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map